Viatris inc. and biocon biologics receive historic approval for first interchangeable biosimilar semglee® (insulin glargine-yfgn injection) for the treatment of diabetes

Pittsburgh and bengaluru, india, july 28, 2021 /prnewswire/ -- viatris inc. (nasdaq: vtrs) and biocon biologics ltd. (a subsidiary of biocon ltd.

VTRS Ratings Summary

VTRS Quant Ranking